1
|
Pang L, Xue X, He Y, Wang C, Han L, Li M, Qi H, Li C, Lu J. The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study. J Inflamm Res 2023; 16:3937-3947. [PMID: 37706063 PMCID: PMC10497051 DOI: 10.2147/jir.s424820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Accepted: 09/01/2023] [Indexed: 09/15/2023] Open
Abstract
Purpose Higher baseline serum urate or higher initial urate-lowering medication dose increased risk of gout flares during urate-lowering therapy (ULT) initiation. The decrease in serum urate may play a crucial role in this process. Therefore, we aim to explore the relationship between decrease in serum urate and the risk of gout flares during ULT initiation. Patients and Methods A 12-week prospective cohort study of Chinese male gout patients was conducted at Shandong Provincial Clinical Research Center for Immune Diseases and Gout in China. Patients were grouped by baseline serum urate (7-7.9 mg/dL, 8-8.9 mg/dL and ≥9 mg/dL). All patients received febuxostat 20 mg daily during weeks 0-4, then escalated to 40mg during weeks 4-12 if serum urate >6mg/dL. The main outcomes were the number of gout flares and the decrease in serum urate. Poisson regression was performed. Results A total of 282 participants were enrolled, of whom 260 completed (84, 87 and 89 in each group) from March 2021 to December 2021. A 44.2% of all participants experienced at least one gout flare. In the multivariate Poisson regression 1, Δ serum urate 0-12 weeks (IRR 1.184, 95% CI, 1.062-1.320; P=0.002), the number of gout flares before treatment 1 year (1.017, 1.010-1.024; P<0.001) and tophus (1.580, 1.023-2.440; P=0.039) were independently associated with the number of gout flares. While in the multivariate Poisson regression 2, baseline serum urate (1.256, 1.050-1.503; P=0.013) and the number of gout flares before treatment 1 year (1.014, 1.007-1.022; P<0.001) were independently associated with the number of gout flares, Δ serum urate 0-12 weeks (1.055, 0.923-1.207; P=0.433) was no longer a risk factor. Conclusion ULT-induced gout flares depend on the degree of decrease in serum urate, which is affected by baseline serum urate. Higher baseline serum urate and greater decrease in serum urate lead to higher risk of gout flares.
Collapse
Affiliation(s)
- Lei Pang
- Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Institute of Metabolic Diseases, Qingdao University, Qingdao, 266003, People’s Republic of China
| | - Xiaomei Xue
- Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Institute of Metabolic Diseases, Qingdao University, Qingdao, 266003, People’s Republic of China
| | - Yuwei He
- Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Institute of Metabolic Diseases, Qingdao University, Qingdao, 266003, People’s Republic of China
| | - Can Wang
- Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Institute of Metabolic Diseases, Qingdao University, Qingdao, 266003, People’s Republic of China
| | - Lin Han
- Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Institute of Metabolic Diseases, Qingdao University, Qingdao, 266003, People’s Republic of China
| | - Maichao Li
- Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Institute of Metabolic Diseases, Qingdao University, Qingdao, 266003, People’s Republic of China
| | - Han Qi
- Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Institute of Metabolic Diseases, Qingdao University, Qingdao, 266003, People’s Republic of China
| | - Changgui Li
- Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Institute of Metabolic Diseases, Qingdao University, Qingdao, 266003, People’s Republic of China
| | - Jie Lu
- Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
- Institute of Metabolic Diseases, Qingdao University, Qingdao, 266003, People’s Republic of China
| |
Collapse
|
2
|
Lertnawapan R, Jatuworapruk K. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout. Clin Rheumatol 2020; 40:255-262. [PMID: 32607660 DOI: 10.1007/s10067-020-05262-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 06/02/2020] [Accepted: 06/23/2020] [Indexed: 12/19/2022]
Abstract
OBJECTIVE The objectives of our study were to compare the efficacy of febuxostat with allopurinol in Thai subjects with gout, as well as to determine the predictive factors of responsiveness to urate-lowering agents and to evaluate the safety of febuxostat in a real-world setting. METHODS The study was a retrospective cohort study; a total of 354 gout patients were recruited from February 2015 to November 2018. The patients were categorized according to prescription of allopurinol or febuxostat. Demographic data, comorbidities, concomitant medications, gout-related clinical parameters, and the laboratory results were collected. The serial serum urate (sUA) levels were recorded at the beginning of the treatment (baseline), and after treatment at 12 weeks, 18 weeks, and 27 weeks. The primary efficacy endpoint was the achievement of target urate of < 6 mg/dl in people taking febuxostat, compared with those taking allopurinol. The secondary endpoints were the predictive factors of achieving target urate level and adverse drug reactions in patients taking febuxostat. Multivariable regression analysis was used to determine factors associated with achieving target serum urate. RESULTS After the treatment, the febuxostat groups had significantly lower mean sUA compared with the allopurinol groups across all follow-up periods. The proportion of people who achieved target serum urate was also higher in the febuxostat groups compared with the allopurinol groups throughout the follow-up periods. The multivariable regression analysis showed that febuxostat 40 mg (OR = 10.96 (95% CI 4.32-27.80); p value < 0.001), febuxostat 80 mg (OR = 9.54 (95% CI 3.91-23.28), smoking (OR = 2.35 (95% CI 1.13-4.91); p value = 0.023), and low baseline serum urate (OR = 0.62 (95% CI 0.52-0.74); p value < 0.001) were associated with the achievement of target serum urate. No adverse drug reaction from febuxostat was observed even among people with renal insufficiency. CONCLUSION In a Thai cohort, people receiving febuxostat are more likely to achieve target serum urate level, compared with people receiving allopurinol. Febuxostat (40 or 80 mg), smoking, and low baseline serum urate were associated with the achievement of target serum urate. KEY POINTS • Febuxostat showed superior urate-lowering efficacy compared with allopurinol in an Asian population. • In addition to febuxostat, lower baseline serum urate level and history of smoking were associated with achieving target serum urate in gout patients.
Collapse
Affiliation(s)
- Ratchaya Lertnawapan
- Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Thammasat University (Rangsit Campus), 99/209 Paholyotin Road, Khlong Luang, Pathum Thani, 12120, Thailand
| | - Kanon Jatuworapruk
- Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Thammasat University (Rangsit Campus), 99/209 Paholyotin Road, Khlong Luang, Pathum Thani, 12120, Thailand.
| |
Collapse
|